Details for Patent: 8,580,765
✉ Email this page to a colleague
Which drugs does patent 8,580,765 protect, and when does it expire?
Patent 8,580,765 protects EPCLUSA, HARVONI, SOVALDI, and VOSEVI, and is included in seven NDAs.
Protection for EPCLUSA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has eighty-nine patent family members in thirty-six countries.
Summary for Patent: 8,580,765
| Title: | Nucleoside phosphoramidate prodrugs |
| Abstract: | Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I. |
| Inventor(s): | Michael Joseph Sofia, Jinfa Du, Peiyuan Wang, Dhanapalan Nagarathnam |
| Assignee: | Gilead Sciences Inc |
| Application Number: | US13/609,614 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,580,765 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
| Patent landscape, scope, and claims: |
More… ↓ |
Drugs Protected by US Patent 8,580,765
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | EPCLUSA | sofosbuvir; velpatasvir | PELLETS;ORAL | 214187-001 | Jun 10, 2021 | RX | Yes | No | 8,580,765*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Gilead Sciences Inc | EPCLUSA | sofosbuvir; velpatasvir | PELLETS;ORAL | 214187-002 | Jun 10, 2021 | RX | Yes | Yes | 8,580,765*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | PELLETS;ORAL | 212477-001 | Aug 28, 2019 | RX | Yes | No | 8,580,765*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | PELLETS;ORAL | 212477-002 | Aug 28, 2019 | RX | Yes | Yes | 8,580,765*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Gilead Sciences Inc | SOVALDI | sofosbuvir | PELLETS;ORAL | 212480-001 | Aug 28, 2019 | RX | Yes | No | 8,580,765*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Gilead Sciences Inc | SOVALDI | sofosbuvir | PELLETS;ORAL | 212480-002 | Aug 28, 2019 | RX | Yes | Yes | 8,580,765*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,580,765
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2203462 | ⤷ Start Trial | 214 5029-2014 | Slovakia | ⤷ Start Trial |
| European Patent Office | 2203462 | ⤷ Start Trial | C300704 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2203462 | ⤷ Start Trial | PA2014040 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2203462 | ⤷ Start Trial | CA 2014 00061 | Denmark | ⤷ Start Trial |
| European Patent Office | 2203462 | ⤷ Start Trial | 1490066-6 | Sweden | ⤷ Start Trial |
| European Patent Office | 2203462 | ⤷ Start Trial | C20140035 00135 | Estonia | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
